CONVINCE is a European, multicenter, prospective randomized controlled study that compares two renal replacement therapy methods high-dose hemodiafiltration and high-flux hemodialysis. The aim of the study is to compare the two therapy methods hemodialysis and hemodiafiltration with respect to the overall mortality rate. Secondary goals are also the comparison of the two therapies with regard to cause-specific mortality, morbidity, health-related quality of life and cost effectiveness.

The CONVINCE consortium is headed by Dr. Peter Blankestijn (UMC Utrecht) and is complemented by the UCL Center for Nephrology, the George Institute for Global Health, Julius Clinical, Fresenius Medical Care, Diaverum Renal Service Group, B Braun Avitum, University of Bari Aldo Moro and the Medical Clinic with a focus on psychosomatics of the Charité - Universitätsmedizin Berlin.

The CONVINCE study is funded within the framework of the Horizon2020 research and innovation program of the European Union (Grant Agreement No 754803) over a period of 5 years (2018-2022).